Dr. Eduardo Castañón Álvarez

Dr. Eduardo Castañón Álvarez, a highly regarded oncology specialist at Clínica Universidad de Navarra in Pamplona, Spain, brings a wealth of experience and unwavering clinical expertise to his practice. With six years in the field, Dr. Castañón Álvarez is recognized for his proficiency in diagnosing neoplasms and providing comprehensive treatment for various oncological lesions affecting the body. Notably, he holds ESMO MORA certification, reflecting his commitment to the highest standards of oncological care. Dr. Castañón Álvarez's educational journey includes a bachelor's degree in medicine from Navarra University in 2009, followed by specialization in oncology at the same institution until 2015. During this period, he earned the title of Doctor of Medicine. His dedication to continuous learning is evident through his internship at the Gustave Roussy Institute, where he focused on trials conducted by the DITEP group from 2015 to 2017. Additionally, he holds a master's degree in biostatistics and molecular oncology. In his professional career, Dr. Castañón Álvarez has emerged as a key figure in the oncology sector at Navarra Hospital, maintaining his association with the institute since 2015. He also holds prominent roles as a leading professor at Navarra University and the MIR academy. Actively engaged in the academic and research community, he is associated with prestigious societies and organizations, including the Spanish (SEOM), American (ASCO), and European (ESMO) cancer societies. Furthermore, he contributes to cancer research on an international scale as a member of the American (AACR) and European (EORTC) cancer research organizations. Dr. Eduardo Castañón Álvarez's notable achievements extend beyond his clinical practice, with participation in over 50 communications at global conferences and co-authorship of eight books aimed at students specializing in the field. His research contributions include the publication of 38 articles in globally recognized journals, showcasing his commitment to advancing oncological knowledge and treatment strategies.